My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Royalty Pharma PLC (RPRX)
RPRX nasdaq
United States
Royalty Pharma

Royalty Pharma Stock Analysis & Ratings

Royalty Pharma Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The Royalty Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


RPRX Stock Stats

Previous Close$42.08
Bid0 x 0
Ask0 x 0
Today’s Range$41.25 - $42.3998
52-Week Range$34.86 - $53.23
Average Volume2.35M
Market Cap$17.99B
P/E Ratio21.6
Earnings DateFeb 16, 2022
Dividend & Yield0.68 (1.62%)
Ex-Dividend DateNov 18, 2021

Company Description

Royalty Pharma PLC

New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
Pablo Legorreta
110 East 59th Street, New York, NY, 10022, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was Royalty Pharma’s price range in the past 12 months?
Royalty Pharma lowest stock price was $34.86 and its highest was $53.23 in the past 12 months.
    What is Royalty Pharma’s market cap?
    Royalty Pharma’s market cap is $17.99B.
      What is Royalty Pharma’s price target?
      The average price target for Royalty Pharma is $49.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $50.00 ,the lowest forecast is $48.00. The average price target represents 16.97% Increase from the current price of $41.89.
        What do analysts say about Royalty Pharma?
        Royalty Pharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Royalty Pharma’s upcoming earnings report date?
          Royalty Pharma’s upcoming earnings report date is Feb 16, 2022 which is in 80 days.
            How were Royalty Pharma’s earnings last quarter?
            Royalty Pharma released its earnings results on Nov 10, 2021. The company reported $0.727 earnings per share for the quarter, beating the consensus estimate of $0.7 by $0.027.
              Is Royalty Pharma overvalued?
              According to Wall Street analysts Royalty Pharma’s price is currently Undervalued.
                Does Royalty Pharma pay dividends?
                Royalty Pharma pays a Semiannually dividend of $0.17 which represents an annual dividend yield of 1.62%. Royalty Pharma’s last Semiannually dividend payment was on Dec 15, 2021. Royalty Pharma’s upcoming ex-dividend date is Nov 18, 2021
                  What is Royalty Pharma’s EPS estimate?
                  Royalty Pharma’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Royalty Pharma have?
                  Royalty Pharma has 429,510,000 shares outstanding.
                    What happened to Royalty Pharma’s price movement after its last earnings report?
                    Royalty Pharma reported an EPS of $0.727 in its last earnings report, beating expectations of $0.7. Following the earnings report the stock price went up 1.496%.
                      Which hedge fund is a major shareholder of Royalty Pharma?
                      Among the largest hedge funds holding Royalty Pharma’s share is Berkshire Hathaway Inc. It holds Royalty Pharma’s shares valued at 475M.

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis